Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients
March 31, 2023 08:03 ET
|
Fennec Pharmaceuticals Inc.
~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in Pediatric Patients with Localized, Non-metastatic Solid Tumors~ ...
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results
March 30, 2023 05:55 ET
|
Fennec Pharmaceuticals Inc.
~ U.S. Commercial Team in Place with PEDMARK® Launch Off to Solid Start Following FDA Approval of PEDMARK® in September 2022 ~ ~ Company Has Approximately $23.8 Million in Cash ~ RESEARCH...
Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA
January 31, 2023 06:00 ET
|
Fennec Pharmaceuticals Inc.
~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ~...
Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients
January 25, 2023 07:19 ET
|
Fennec Pharmaceuticals Inc.
~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-metastatic Solid Tumors ~ ~...
Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update
November 11, 2022 07:10 ET
|
Fennec Pharmaceuticals Inc.
~ In September 2022, FDA Approved PEDMARK®, the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized,...
Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States
October 17, 2022 08:00 ET
|
Fennec Pharmaceuticals Inc.
~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~ ~ Fennec HEARS™ Program Offers Comprehensive Patient...
Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor
September 26, 2022 07:35 ET
|
Fennec Pharmaceuticals Inc.
~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of...
Fennec Pharmaceuticals Announces FDA Approval of PEDMARK® (Sodium Thiosulfate Injection)
September 21, 2022 07:00 ET
|
Fennec Pharmaceuticals Inc.
~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ...
Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor
August 22, 2022 07:04 ET
|
Fennec Pharmaceuticals Inc.
~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~ ~ Fennec Has the Potential to Access...
Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update
August 12, 2022 06:59 ET
|
Fennec Pharmaceuticals Inc.
~ PEDMARKTM FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ~ Commercial Team Built Out In Anticipation of U.S. Launch of PEDMARKTM ~ ~ Recently Announced...